chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a healthcare worker referring to a patient of unknown age and gender. On 24-JUN-2015, the patient was vaccinated with improperly stored dose of (Oka/Merck) VARIVAX (lot number, dose and route were unknown). No adverse experiences were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received from a certified medical assistant concerning a female patient who was vaccinated with a second 0.5ml dose of varicella virus vaccine live (Oka/Merck) (Lot # 0851U). There was no concomitant medication.  The patient developed an injection site reaction after vaccination with the second dose of varicella virus vaccine live (Oka/Merck). Symptoms were described as a big red rash at the site of injection. The rash was described as being "puffy" and a "big circle". The physician prescribed an unspecified medication for the symptoms. No further information was available. Unspecified medical attention was sought. No product quality complaint was involved. This is the first of three cases for this reporter. Additional information has been requested.
Began having right hip and  groin pain on 11/23/22, admitted to Hospital on 1/2/23 with acute Pulmonary Embolism and acute Deep Vein Thrombosis in right popliteral and peroneal veins.leg. Admitted to ICU on 1/2/23, Heparin administered and released on 1/6/23 with Eliquis.
This spontaneous report was received from a healthcare worker (also reported as nurse) refers to a patient of unknown age and gender. Concurrent conditions, medical history and allergies were not reported. On 22-DEC-2014, the patient was vaccinated with a dose of GARDASIL, (strength, dose, route and anatomical location were not reported), (lot # H020901, expiration date: 05-JUL-2015), which was incorrect stored since 02-DEC-2014. No adverse effects were reported and no product quality complaint (PQC) was filled. This is one of several reports received from the same reporter. Additional information has been requested.
in bed with aches and pain; has two messed up knees and leg problems; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program.  A 64 year-old male patient received bnt162b2 (BNT162B2), administration date Aug2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN (non-serious) with onset 2021, outcome "unknown", described as "in bed with aches and pain"; ARTHROPATHY (non-serious) with onset 2021, outcome "unknown", described as "has two messed up knees and leg problems".  Additional information: The patient had his first dose on an around 19Aug2021 and reported that he was in bed with aches and pain afterwards. The patient had two messed up knees and leg problems and it was because of that.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
I woke up in the night with a fungus infection of the urinary, vaginal, pubic mound, and anal area.  I was in extreme pain and called Dr  first thing Monday morning for an emergency appt.  she prescribed diflucan and a fungal cream.   The fungus persisted for 6 1/2 weeks rendering me incapable  of caring for myself.  The fungus was treated by her with 4 different fungal creams .  One of which include a steroid.  The final cream was a compounded cream.  I saw here 3 times in the office and spoke with here once on the phone on April 10th.   I have just had my 6 month well visit with Dr.  my GP today and he advised I should contact the Clinic and report my adverse reaction.  He is an infection disease specialist.
This spontaneous report as received from a health care worker concerning to unspecified number of patients of unknown age and gender. Patients concurrent conditions and relevant medical history was not reported. On an unknown date, unspecified number of patients were vaccinated with improperly stored M-M-R II (lot number, dose and route unspecified). Concomitant medications were not reported. No adverse symptoms were reported. The temperature excursions that were reported for M-M-R II was supported excursion with in-house stability data. The outcome of the events was unknown. The causality of the events with M-M-R II was not reported. Product quality issue was not involved. This is one of the several reports from the same reporter. Additional information has been requested.
rash which looked like welts with blisters,size of the fingertip; This spontaneous case was reported by a consumer and describes the occurrence of RASH VESICULAR (rash which looked like welts with blisters,size of the fingertip) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 053E4A) for COVID-19 vaccination.     Concurrent medical conditions included COPD.    On 26-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Aug-2021, the patient experienced RASH VESICULAR (rash which looked like welts with blisters,size of the fingertip). The patient was treated with HYDROCORTISONE ongoing since an unknown date for Blistery rash, at a dose of 1 dosage form and ANTIHISTAMINES ongoing since an unknown date for Blistery rash, at a dose of 1 dosage form. At the time of the report, RASH VESICULAR (rash which looked like welts with blisters,size of the fingertip) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information was mentioned by reporter.
Noted soreness/redness (1" diameter) next AM (approximately 4-28-15 9:00 AM) states "it felt bruised at first" with pruritus or drug. No other sx. Very slightly elevated approximately equal to 1 mm raised. Required varicella series for higher education (1st dose). Hx of chickenpox in 2000.
spasms in the lower back; headache; little dizziness; tiredness; weakness; having pain and tightness in her neck and shoulders; having pain and tightness in her neck and shoulders; having pain and tightness in her neck and shoulders; having pain and tightness in her neck and shoulders; she describe as pain and tightness in her neck and shoulder and the end it is now moved down to her lower back; This is a spontaneous report received from a contactable consumer (patient). A 54-years-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 05Apr2021 (Lot Number: ER8737; Expiration Date: 31Jul2021) as SINGLE DOSE for covid-19 immunisation. The patient medical history was not reported. Concomitant medication(s) included acetylsalicylic acid (ASPIRIN); colecalciferol (VITAMIN D3); paracetamol (TYLENOL); zinc chloride; lactobacillus acidophilus (FLORAJEN) and Multivitamin. The patient took the first dose of bnt162b2 lot number EN6204 on 15Mar2021 in left arm for Covid-19 immunization. The patient experienced the side effect of muscle spasm in her lower back, a headache, a little bit of dizziness, weakness and tiredness. She had a pain in the neck and shoulder that was kind of more like tightness rather than pain, that she describe as pain and tightness in her neck and shoulder and the end it is now moved down to her lower back she said her neurologist gave her an injection of some kind and she is taking goody powder to help with that pain, she said it goes away for little while and comes right back and she said she also know another female who has the same pain on neck and shoulder after she received the Pfizer vaccine as well. Treatment for events was Tylenol, rapid Tylenol, goody's powder. The outcome was unknown.   No follow-up attempts are needed. No further information is expected.
Reports felt "woozy,dizzy" when got home. approx 1 1/2 hr later had some difficulty breathing along with burning sensation of face and eyes. did not call or seek care at that time. Went to school health nusre where she works next am:continued with above symptoms, along whith heart racing and rising BP; EMT called went to ER
Severe burning in injection site immediately.  Severe headache starting 3-5 hours since vaccination.  Still experiencing as of 1/15/2021. On 1/14/2021 experienced throbbing under ear to jaw bone.
The mother of the pt states that she related of symptoms in both legs, back and neck. Wyeth doctor ordered lab work. Areas of petichiae in lateral and posterior arm. The pt is now improving with the left leg appearing to be gone. All lab work was normal.
Bloody nose that lasted 1 half hour.; This spontaneous case was reported by a patient and describes the occurrence of EPISTAXIS (Bloody nose that lasted 1 half hour.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, the patient experienced EPISTAXIS (Bloody nose that lasted 1 half hour.). On 16-Feb-2021, EPISTAXIS (Bloody nose that lasted 1 half hour.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.   No treatment information was provided.
Information has been received from a nurse practitioner concerning a female in her 70's, with a history of Guillain-Barre syndrome who in Spring, approximately in March 2008, was vaccinated with ZOSTAVAX. On 01-MAY-2008, the patient developed zoster and post herpetic neuralgia. The patient has continued to have recurrent trigeminal lesions and post Herpetic Neuralgia. It was reported that the patient could not work. The patient's herpes zoster and post herpetic neuralgia were considered to be disabling. The patient sought medical attention in the physician's office. Additional information has been requested.
Patient received his second Pfizer vaccination on 1/14 and had no immediate adverse reaction. He states he developed cardiac symptoms and was seen in the ER on 1/16. He was diagnosed with new onset atrial fibrillation. No previous history of atrial fibrillation.
Information has been received from a nurse referring to a patient of unknown age and gender. The patient's medical history, concomitant therapy and concurrent condition were not provided. On 06-SEP-2016, the patient was vaccinated with a dose of VARIVAX (strength, dose and frequency were unknown; lot number M010482 with expiration date 01-MAR-2018). VARIVAX was improperly reconstituted with "0.5 ml, from a separate, 10 ml single dose vial of Sterile Water for injection, for drug diluent use, manufactured by Hospira, lot # 54-152-DK with expiration date 01-JUN-2018" instead of the Merck supplied diluent. No adverse effect reported. This is one of the twelve reports that received from the same source. Additional information has been requested.
This spontaneous report as received from a physician refers to a 16 year old female patient. Without pertinent medical history, drug reactions or allergies. On 20-NOV-2013, the patient was vaccinated with a dose of GARDASIL Lot No. J007354; Expiration date: 20-FEB-2016, 0.5 ml, intramuscular for prevention of human papilloma virus (HPV). Secondary therapy was not reported. There was no concomitant medication. The physician reported that the patient initially experienced swelling (approximately in November 2013) and a lump after receiving GARDASIL. On 28-DEC-2013, the patient was seen in the office and ha a palpable, non-tender lump that was "marble sized, approximately 1-2 cm, in size" at the injection site. The outcome of the events was unknown. The patient did not receive treatment for the events. No Lab diagnostics studies were performed. Additional information has been requested.
Swelling of fingers, wrist, hands, elbows, knees, ankles, and most joints. Severe pain in all of the above joints.
The day after immunization, from head to toe broke out in painful, itchy rash. Eczema on my hands flared ten times worse than before. These symptoms lasted for three weeks. I missed work for three weeks, was unable to sleep and pain scale was 10/10.
Information has been received from a pharmacist via a field representative referring to a 74 year old female patient. On 18-OCT-2015 the patient was vaccinated with a dose of ZOSTAVAX, lot # L012039, expiration date unknown (dose, dose #, route and application site were not reported). On an unknown date the patient called the pharmacy to report that she developed "a rash that was raised and red" at the injection site following administration of ZOSTAVAX. It was unknown if the patient received any treatment. The outcome of the event was unknown. The causality was not reported. This is one of several reports received from the same source. Additional information has been requested.
Hepatitis C  This case was reported by a sales representative via a physician and described the occurrence of hepatitis C in a subject (age and gender unspecified) who received hepatitis b vaccine recombinant (Engerix-B).   On an unspecified date, the patient received a dose of Engerix-B (dose and lot number not provided). At an unspecified time following the administration of Engerix-B, on an unspecified date, the patient experienced hepatitis C. The outcome of the event was not reported.
Same day post vax, the pt developed a fever ranging from 100-101.8. Fever was 103 on 9/21. Seen in clinic 9/22. Pt given Rocephin IM, then started on Augmentin. Fever resolved.
10 days after receiving a flu shot, the pt developed severe muscle pains in the legs and shoulders, followed by bilateral leg weakness and inability to stand unassisted. He demonstrated areflexic quadriparesis, dysarthria, and bifacial weakness, resting tachycardia, hypertension and intermittent diaphoresis. The pain required neurontin.
Acute onset of severe left lower quadrant pain leading to near-syncope and collapse. Severe pain lasted 15-20 min, then decreased intensity for about 12 hrs longer. Transported to ER by ambulance.
intense, overall joint point (especially hands and jaw), lymph nodes on left side under jaw.  Overall fatigue and mild muscle pain.  Injection site pain.  Tylenol took the edge off pain, but  I was unable to perform normal tasks for a few days.
The patient has received two vaccine shots. One Pneumonia shot and one Swine flu shot for 2009. Complaint was increased heart beat, abnormal tiredness. He is currently disabled and has permanent damage to the endocrine system's, no nervous system's, no cardiovascular system's, no pulmonary system's, no respiratory system's, no circulatory system's. He has a heart beat that is currently under control with clonidine, hypertension, essential benign, hyperlipidemia.
Patient's chief complaint was feeling tired and shortness of breath. Patient was hypertensive. Denied dizziness and chest pain. Patient was offered oxygen  supplementation but refused and stated that he felt okay. All symptoms resolved except fatigue and blood pressure remained slightly elevated.
soreness at the injection site; tiny fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (tiny fever) and INJECTION SITE PAIN (soreness at the injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 039K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Feb-2021, the patient experienced PYREXIA (tiny fever). On 05-Feb-2021, the patient experienced INJECTION SITE PAIN (soreness at the injection site). The patient was treated with NAPROXEN SODIUM (ALEVE) for Fever and Injection site pain, at an unspecified dose and frequency. On 05-Feb-2021, PYREXIA (tiny fever) had resolved. At the time of the report, INJECTION SITE PAIN (soreness at the injection site) had resolved.            Concomitant product use was not provided by the reporter.
APPROXIMATELY 9 AM PATIENT BELIEVES HE PASSED OUT BUT NOT OBSERVED BY ADULT.  BELIEVES HE FELL ON THE FLOOR.  HE FELT DIZZY.  TOLD MOM THIS AFTER SCHOOL.  ONE CHILD SAW HIM FALL.  BELIEVES HIT HEAD ON FLOOR.  BP CHECKED BY SCHOOL NURSE WNL.
Weakness, joint pain, migraine, anxiety, depression, hair loss, insomnia, blackouts, muscle pain, skin disorder, hearing loss, loss vision, finger and toes go numb for min. DX: PTSD Chronic low back pain Migraine Major depression/single acute URI HX of affective disorder.
This spontaneous report was received from a nurse refers to an unspecified number of patients of unknown age and gender. The patients medical history, concurrent conditions and concomitant medications were not reported. On an unknown date(s), the patients were vaccinated with improperly stored doses of PNEUMOVAX23 from lot# M037533 with expiry: 17-MAY-2018, for prophylaxis (dose, route and anatomical location not reported). The vaccine lot had a temperature excursion of -1.7 degree Celsius for 1 hour and 10.8 degree Celsius for 2 hours. No adverse effects were reported. The vaccines had no previous temperature excursion. The temperature excursion was identified by data logger. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1706USA001439: US-009507513-1706USA001439:
parotitis,  acute.   Also occurred after 2nd injection in April 2021, but I didn?t report it. After both injections  seems like a pattern.  Both times lasting several days.
No additional adverse effects reported; received one dose of improperly stored VARIVAX; This spontaneous report was received from a nurse and refers to a patient of an unknown age and gender. Information about concomitant medications, pertinent medical history and drug reactions or allergies was not provided. On 15-APR-2020, the patient was vaccinated with one dose of an improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) injection, lot number: S002393, expiration date: 23-JAN-2021 (strength, dose, vaccination scheme and route of administration were not provided) as prophylaxis. Sterile diluent (STERILE DILUENT) which was used to reconstitute the vaccine had been properly stored. The administered dose of vaccine experienced a temperature excursion of -12.5 degrees Celsius (C) for 15 minutes. The vaccine also experienced previous temperature excursion of -13.5 degrees C for 18 minutes. Digital data logger was involved. No additional adverse effects were reported.
9 cm x 7 cm area of erythema at injection site after 24 hours, temp of 100.5, body aches, fatigue all of which had resolved by 9 AM 01/14/2022
Admitted for COVID, tested positive 7 days PTA, exposure to wife at home with COVID. Treated with steroids, lovenox, zinc, vit-c, eliquis, singulair. Developed AKI and new-onset Afib. Fully vaccinated. Did not require supplemental O2. Improved and discharged home.
Janssen COVID-19 Vaccine EUA, I have a sore arm at the injection site.
Patient is a 31 year old, parent of a patient in office approximately 10 min after receiving the vaccine, patient began have difficulty breathing & staring distantly. No hives or wheezing. O2 given but continued respiratory distress & poor responsiveness code blue called & transferred via EMS to hosp. at that time she was alert & sitting up conversing.
Toes cramping severely once then progressed to extreme pain like a wave starting at toes then moving up entire body from 7 pm at night until the next day around 5 pm, this is not the worst. I did not feel well for over a month after 2nd shot. I had my annual physical feb 8 one week after shot. Those lab results reported I had stage 3a kidney failure. My GFR results were 51.  as in stage 3a kidney failure!  And my MCHC level was 31.7. I never had issues with either of these before.   I have been retested March 8 and am back to normal results.
Vial from previous day left out. Administered more than 12 hours but less than 24 hours after 1st poke
sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for an unreported indication: FLU VACCINE VII.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm). At the time of the report, PAIN IN EXTREMITY (sore arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. Treatment medications were not provided by the reporter.    This case was linked to MOD21-089331 (E2B Linked Report).; Sender's Comments:  MOD21-089331:cross linked id - husband case
The afternoon Flu-Mist given in school clinic, child complained to mom of H/A when arrived home - temp done:  99.9/oral.  Given fever reducer and temp went down to normal.  The next day (10/18/13) at school, child reported to school nurse with H/A and temp of 101/oral.  Parent called - child went home; temp spiked to 103/oral.  Fever reducer given - did not go under 101/oral all weekend.  10/21/13, returned to school with temp back to normal.
4 days after vaccination, pt. had office visit for reported extreme right arm pain unrelieved by OTC analgesics. Eval. showed no redness, swelling, or warmth.
Patient received Pfizer monovalent instead of Pfizer bivalent as a Covid-19 booster dose.
Repeated breakouts in my scalp, moving to my underarms, and then on my chest.  This is the 3rd bad breakout I've had.  They are large bumps that makes me want to itch my scalp off.
On 6/1/23 immediately after injection, left arm numbness for three days, fatigue 3 days, dizziness one week, purple mottled palms hands one week. Continued numbness tingling on/off for two weeks. On 6/25/23 numbness tingling to right side of face, 6/26 tingling worsening and lower right lip droop. Also feeling cold and hot sensations to right side of face. I went to the ER got imaging, Doctor and Dr at Med Center diagnosed me with facial peripheal nerve inflammation and neuropathy.  On 6/28 condition worsening with right eye blurred vision and worsening of facial numbness and tingling.
Swelling in throat, slight tongue swelling, and hives in face, neck, and chest.
Patient became ill 4 days after receiving the vaccine dose. Fevers, chills, vomiting and severe URI symptoms. Has not resolved at this time. I have contacted his PCP and will bring him for a sick visit if he is not better by tomorrow.
Tested positive after 7 days of taking the vaccine; Tested positive after 7 days of taking the vaccine; This is a spontaneous report from a contactable Pharmacist.  A female patient of unknown age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, on an unknown date at single dose for COVID-19 immunisation. Medical history and concomitant medications were unknown. The patient tested positive after 7 days of taking the vaccine. Patient also received the "Bam antibodies", monoclonal antibody. Outcome was unknown. Information on the lot/batch number has been requested.; Sender's Comments: The association between the event lack of effect (tested positive) with BNT162b2 can not be completely excluded.